
Please try another search
By Senad Karaahmetovic
Novavax (NASDAQ:NVAX) shares are down over 5% today after a JPMorgan analyst downgraded to Underweight from Neutral.
The analyst also slashed the price target by 80% to $27 to reflect softening demand for the company's Covid-19 vaccine Nuvaxovid.
“Despite the weak second quarter print and downward revenue guidance revision for FY22, our read of the recent vaccine dynamic in the EU and US would suggest further guidance cuts are in the offing, while also pointing to mid- and longer-term headwinds to meaningful Nuvaxovid uptake,” he wrote to clients in a note.
Novavax is operating in a difficult environment, where in addition to growing macro headwinds the management’s execution is also attracting attention. Along these lines, the analyst sees “the potential for dilutive pressure to NVAX shares over the next 6-12 months.”
Net-net, the analyst expects to see a period of underperformance from NVAX shares on the back of the challenging fundamentals and the further decline in the COVID trade sentiment.
Novavax stock trades at the lowest levels since May 2020.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.